NCT00770601View on ClinicalTrials.gov

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 26, 2009

Primary Completion Date

February 17, 2011

Study Completion Date

February 17, 2011

Conditions
NOMIDCINCA Syndrome
Interventions
DRUG

Canakinumab

Trial Locations (1)

20892

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 9, Bethesda

Sponsors
All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Novartis Pharmaceuticals

INDUSTRY